CREATION AND ASSESSMENT OF A MOUTH DISSOLVING FILM CONTAINING LURASIDONE FOR THE TREATMENT OF PSYCHOSIS

Abstract

Because oral thin dissolving films or strips include water-soluble polymers, they dissolve or adhere to salivary mucosa in the mouth cavity or on the tongue in a matter of seconds, releasing the medication as fast as possible. The ideal thin film should have all the characteristics of a drug delivery system, including an acceptable formulation stability, a sufficient drug loading capacity, quick dispersion or dissolution, or extended application. Lurasidone must be formulated into buccal patches, and this medication is appropriate for this use. There are several uses for bioadhesive formulations in the therapy of illnesses, both locally and systemically. They must also be biocompatible, harmless, and biodegradable. nine fast-dissolving film formulations with varying polymer concentrations were created using lurasidone as a model drug candidate. Through the preparation of many oral dispersible film formulations, the impact of the polymer's nature was investigated. The release of the several formulations that included a blend of polymers was discovered to be in the following order: The optimal formulations for medication release and formulations are LMDF6>LMDF3. The most releases in less than an hour were discovered to be LMDF5, LMDF2, LMDF4, and LMDF1.The findings of the release kinetics investigation demonstrated that every formulation more closely followed the first order drug release profile, meaning that the release rate was dependent on the drug's starting concentration. The non-fickian or super case II transport mechanism was shown by the slope values of the Korsmeyer-Peppas plot.

Keywords: Formulation and evaluation, Lurasidone, Mouth dissolving film, Psychosis